ALTO NEUROSCIENCE INC (ANRO)

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

/PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC)...

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc....

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Alto Neuroscience Enters Oversold Territory (ANRO)

ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm

Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants

Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the second quarter of 2...

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024

ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Oversold Conditions For Alto Neuroscience (ANRO)

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

Friday 7/12 Insider Buying Report: ANRO, AHH

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On

Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024

ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.

ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the first quarter of 20...